Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous myeloid dendritic cells pulsed with inactivated autologous HIV-1
- Development stage
- Phase 2
- Lead developer
- Hospital Clínic de Barcelona
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Intradermal
01
Overview
A personalized therapeutic vaccine candidate for the treatment of chronic HIV-1 infection. The therapy utilizes a patient's own monocyte-derived myeloid dendritic cells (MD-DCs) which are loaded ex vivo with heat-inactivated autologous HIV-1. By presenting the full complement of the patient's specific viral antigens, the vaccine is designed to stimulate a robust and durable HIV-specific cellular immune response, primarily involving CD4+ and CD8+ T-lymphocytes. The goal is to achieve functional control of viral replication, potentially allowing for the discontinuation of combination antiretroviral therapy (cART). It has been primarily investigated by the Hospital Clínic de Barcelona in Phase II clinical trials.
- Other names
- autologous monocyte-derived myeloid dendritic cells loaded with heat-inactivated autologous HIV-1RISVAC02 vaccineRISVAC-02 vaccineRISVAC 02 vaccineDCV-2 vaccineDCV2 vaccineDCV 2 vaccineautologous dendritic cell therapeutic HIV-1 vaccine
02
Targets
HIV-1 antigens
Beyond the preview
Go deeper on autologous myeloid dendritic cells pulsed with inactivated autologous HIV-1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous myeloid dendritic cells pulsed with inactivated autologous HIV-1.